Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection [Phase 2]

View source ↗

Summary

This Phase 2 trial assessed the efficacy, safety, and pharmacokinetics of ABT-450/r in combination with ABT-333 and ribavirin in treatment-naïve and non-respond…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-333 (deleobuvir) (deleobuvir)
• ABT-450 (paritaprevir) (paritaprevir)
• Ribavirin (ribavirin)
• Ritonavir (Ritonavir)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Chronic Hepatitis C Infection, Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2015-01-08